The U.S. Food and Drug Administration (FDA) announced it has completed a final and comprehensive framework to oversee regenerative medical products, including cellular therapies. The cosmetics industry has leveraged these technologies as well, and as medicine and cosmetic treatments become more “personal” in nature, it will be all the more important the industry is aware of where the FDA draws the line for use of these materials.
According to the FDA, the new framework builds upon an existing risk-based regulatory approach in order to clearly describe what products are regulated as drugs, devices and/or biological products.
Nanoparticles have a bad reputation among the general public. There is great uncertainty as to…
In an ever-changing and increasingly competitive hair care market, sensory profiling is a real asset…
Taobé Consulting specializes in helping cosmetic brands navigate complex European and UK regulatory frameworks, providing…